NCT01662284View on ClinicalTrials.gov

Study of 124I-NM404 in Advanced Solid Malignancies

TerminatedOBSERVATIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck Cancer
Interventions
DRUG

124I-NM404

124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.

Trial Locations (1)

53792

University of Wisconsin Carbone Cancer Center, Madison

Sponsors
All Listed Sponsors
collaborator

Cellectar Biosciences, Inc.

INDUSTRY

lead

University of Wisconsin, Madison

OTHER